Recom Names MCS Public Relations as Communications Agency of Record.

LOS ANGELES -- Recom Managed Systems, Inc. (OTCBB:RECM), a life-sciences company developing patented heart-monitoring technology, today announced that it has engaged the services of MCS Public Relations, a leader in healthcare communications, to provide public relations support and counsel.

In its role as agency of record, MCS will provide strategic guidance, counsel and support services for all Recom communications activities and initiatives directed to healthcare and business media, as well as to an extensive community of cardiology researchers, clinicians and patients.

"As we work towards the commercialization of our advanced heart-monitoring technology, it will be important to effectively communicate the benefits of our products to the many stakeholders who will influence their rapid adoption and use," said Pamela Bunes, chief executive officer and president of Recom. "We're delighted to be working with MCS as they have a 20-year proven track record of excellence in healthcare communications, with a particularly strong history and expertise in cardiology."

MCS has worked directly with many leading US and international cardiologists and researchers in communicating results from landmark studies in congestive heart failure (ATLAS) coronary artery disease (GUSTO) and myocardial infarction (TIMI trials, ASSENT 2 & 3, ISIS and GISSI) at meetings of the American Heart Association, American College of Cardiology and the European Society of Cardiology. The agency has also provided communications support for more than 20 cardiovascular products, disseminating news and information about clinical trial outcomes, FDA approvals and line extensions.

"Recom represents the vanguard of new technologies that may soon alter how clinicians and hospital staff monitor their cardiovascular disease patients, " said Todd Forte, MCS executive vice president. "We have a unique opportunity to help Recom communicate and share these advancements in heart health monitoring that may someday save lives in a population that is both aging and at increased risk for cardiac events."

Breakthrough ECG Monitoring Technology

Recom's first product, the Model 100 Heart Monitor, is an ambulatory patient heart monitor that uses patented signal-processing technology to record a clinical-quality ECG signal in the presence of "noise," or interference, generated by the patient's body movements and ambient environment. By reducing these interfering factors during recordings, the Recom Model 100 helps general practitioners and cardiologists more accurately detect cardiac abnormalities or changes that may occur during daily activities and allows medical experts to collect extensive, continuous cardiac data over time, which can establish a baseline against which future readings can be compared. The Model 100 provides up to 48 hours of real-time heart monitoring during patients' everyday activities. The Model 100 has received 510(k) clearance from the Food and Drug Administration (FDA).

About Recom Managed Systems, Inc.

Recom Managed Systems, Inc. is an emerging life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal-technology platform, Recom brings clinical-quality physiological signal monitoring to the ambulatory setting.

Recom Managed Systems, Inc. is traded on the OTC Bulletin Board under the symbol RECM.OB. More information is located at http://www.recom-systems.com

About MCS Public Relations

As a valued communications partner to some of the world's leading pharmaceutical companies, medical device innovators and future leaders in biotechnology, MCS has developed a strong reputation as a healthcare public relations and marketing communications company that delivers measurable benefits for its clients. Located in Bedminster, New Jersey, MCS has served more that 80 clients and has represented more than 100 ethical pharmaceutical products and medical devices since the company's founding in 1985. More information is located at http://www.mcspr.com

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity-market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.